Terms: = Ovarian cancer AND PPP2R1A, PR65A, 5518, ENSG00000105568, MGC786, P30153 AND Prognosis
4 results:
1. Uterine serous carcinoma: key advances and novel treatment approaches.
Ferriss JS; Erickson BK; Shih IM; Fader AN
Int J Gynecol Cancer; 2021 Aug; 31(8):1165-1174. PubMed ID: 34210768
[TBL] [Abstract] [Full Text] [Related]
2. [Endometriosis-related ovarian tumors].
Schmidt D; Ulrich U
Pathologe; 2014 Jul; 35(4):348-54. PubMed ID: 24992974
[TBL] [Abstract] [Full Text] [Related]
3. Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers.
Spaans VM; Trietsch MD; Crobach S; Stelloo E; Kremer D; Osse EM; Haar NT; van Eijk R; Muller S; van Wezel T; Trimbos JB; Bosse T; Smit VT; Fleuren GJ
PLoS One; 2014; 9(3):e93451. PubMed ID: 24671188
[TBL] [Abstract] [Full Text] [Related]
4. ppp2r1a mutations are common in the serous type of endometrial cancer.
Nagendra DC; Burke J; Maxwell GL; Risinger JI
Mol Carcinog; 2012 Oct; 51(10):826-31. PubMed ID: 21882256
[TBL] [Abstract] [Full Text] [Related]